

Haematologica
HAEMATOL/2017/169532
Version 3

Incidence of second primary malignancies and related mortality in
imatinib-treated chronic myeloid leukemia patients

Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Francesco Albano, Alessandra Iurlo, Tamara Intermesoli, Elisabetta Abruzzese, Luciano Levato, Mariella D'Adda, Patrizia Pregno, Francesco Cavazzini, Fabio Stagno, Bruno Martino, Gaetano La Barba, Federica Sorà, Mario Tiribelli, Catia Bigazzi, Gianni Binotto, Massimiliano Bonifacio, Clementina Caracciolo, Simona Soverini, Robin Foà, Michele Cavo, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Bacarani, and Gianantonio Rosti
(Collaborative Groups: GIMEMA CML Working Party)

Disclosures: GG has acted as a consultant and received honoraria from Novartis, Bristol-Myers Squibb and Ariad. FC has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad. M Breccia has acted as a consultant for Bristol-Myers Squibb and Novartis, Pfizer and Ariad. AI has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad. EA has acted as a consultant for Novartis, Bristol-Myers Squibb, Incyte and Pfizer. PP has acted as a consultant for Novartis, Pfizer and Ariad. MT has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad. M Bonifacio received funding research from Novartis and has acted as a consultant and received honoraria from Bristol-Myers Squibb, Pfizer, Ariad and Amgen. SS has acted as a consultant for Ariad, Bristol-Myers Squibb, and Novartis. GM has served on the speakers' bureaus of Novartis, Bristol-Myers Squibb and Pfizer. FP has received research support from Novartis, served as advisor for Novartis, Bristol-Myers Squibb and Ariad, and received lecture fees from Novartis and Bristol-Myers Squibb. GS has acted as a consultant for and received honoraria from Bristol-Myers Squibb, Novartis, Ariad and Celgene. GR has acted as a consultant for Novartis, Bristol-Myers Squibb and Ariad, and served on the speakers' bureaus of Novartis, Bristol-Myers Squibb and Roche. M Bacarani has received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad, and served on the speakers' bureaus of Novartis and Bristol-Myers Squibb. The other authors declare no conflict of interest.

Contributions: GG, M Bacarani and GR analyzed the data and wrote the first draft of the manuscript. All the other authors contributed to the design of the study, to the collection of the data and to the final report.